These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 33399181)
21. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study. Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957 [TBL] [Abstract][Full Text] [Related]
22. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria. Andersen NH; Mogensen CE Curr Hypertens Rep; 2002 Oct; 4(5):394-402. PubMed ID: 12217259 [TBL] [Abstract][Full Text] [Related]
23. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. Talbert RL J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609 [TBL] [Abstract][Full Text] [Related]
24. Renoprotective effects of renin-angiotensin-system inhibitors. de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533 [No Abstract] [Full Text] [Related]
25. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients. Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002 [TBL] [Abstract][Full Text] [Related]
26. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942 [TBL] [Abstract][Full Text] [Related]
27. Dual renin-angiotensin system blockade for nephroprotection. Ruggenenti P Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742 [TBL] [Abstract][Full Text] [Related]
29. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E; Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518 [TBL] [Abstract][Full Text] [Related]
30. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Bakris GL Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895 [TBL] [Abstract][Full Text] [Related]
31. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Sarafidis PA; Ruilope LM Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA; Gariani K; Martin PY Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413 [TBL] [Abstract][Full Text] [Related]
33. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease. Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468 [TBL] [Abstract][Full Text] [Related]
34. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis. Salvador GL; Marmentini VM; Cosmo WR; Junior EL Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020 [TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289 [TBL] [Abstract][Full Text] [Related]
36. Compelling drug indications in diabetic and nondiabetic nephropathy. Ritz E; Dikow R; Zeier M Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864 [TBL] [Abstract][Full Text] [Related]
37. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise. El-Haddad B; Reule S; Drawz PE Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442 [TBL] [Abstract][Full Text] [Related]
38. Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. Swift PA; Andrews PA Int J Clin Pract; 2010 Sep; 64(10):1331-3. PubMed ID: 20716138 [No Abstract] [Full Text] [Related]
40. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]